About: Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $10.75 (+1.03%)
XERS NASDAQ Xeris Pharmaceuticals Inc
Xeris Pharmaceuticals Inc share price
Atividade de preço de XERS
Último preço
$ 10,750
Variação (24h)
0,11 USD (1,03%)
Volume
1.74M
Volume (média 4 sem.)
-
Abertura
$ 10,80
Variação do dia
$ 10,71 - $ 10,94
Fechamento anterior
$ 10,64
Último negócio
29 Oct, 8:09 pm GMT+0
Atrasado
29 Oct, 8:09 pm GMT+0
XERS price performance
Atrasado
29 Oct, 8:09 pm GMT+0
quote.marketSignals